TIVC
Tivic Health Systems, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.26
−10.46%Sep 1, 2026, 10:17 UTC
Valion Bio, Inc. signed a letter agreement with 3i, LP to issue Series B and Series C preferred shares and warrants to purchase common stock for an aggregate purchase price of $7,737,000.
Aug 17, 2026, 00:00 UTC
Valion Bio, Inc. appointed Lisa Wolf as Chief Operating Officer and Chief Financial Officer, effective August 16, 2026.
Aug 17, 2026, 00:00 UTC
Valion Bio, Inc. terminated Michael K. Handley as Chief Executive Officer, effective August 16, 2026.
Aug 6, 2026, 00:00 UTC
Valion Bio, Inc. issued 1,287.8685 shares of Series A Non-Voting Convertible Preferred Stock to Statera Biopharma, Inc. and Avenue Venture Opportunities Fund, L.P. as milestone payment consideration in a private placement exempt from registration under Section 4(a)(2) and/or Regulation D.
Jun 18, 2026, 00:00 UTC
Valion Bio, Inc. issued 250 shares of Series B Non-Voting Convertible Preferred Stock and a warrant to purchase 156,026 shares of common stock to 3i, LP in a private placement for $250,000 in proceeds.
Jun 3, 2026, 00:00 UTC
Dean Zikria was elected as a Class II director of Valion Bio, Inc., effective May 28, 2026.